Press Releases
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Comprehensive Analyses Across Interventional and Observational Trials Show that Hippocampal Atrophy Closely Tracks with Memory Loss and Disease Progression, and Is Highly Sensitive to Effects of Disease-Modifying Therapies
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Valiltramiprosate Demonstrates Potential as the First Oral Disease-Modifying Agent to Slow Alzheimer’s Pathology, Indicated by Both Clinical and Volumetric MRI Data
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Publication Describes Efficacy by Disease Severity and Highlights Prespecified Analysis of Mild Cognitive Impairment Stage Patients that Showed Cognitive and Functional Benefits, and Neuroprotective Effects on Brain Atrophy
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Anti-Amyloid Oligomer Action Underpins Valiltramiprosate’s Potential Benefit in Alzheimer’s Disease at MCI Stage of Disease
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Valiltramiprosate Improved Cognition and Function in Prespecified Analysis in Patients at Mild Cognitive Impairment Stage
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
First Interventional Alzheimer’s Drug Trial Focused on High-Risk APOE4/4 Homozygotes with Major Unmet Medical Need for an Effective and Safe Treatment